These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 7637098)

  • 1. Crystallization properties in urine from calcium oxalate stone formers.
    Tiselius HG; Bek-Jensen H; Fornander AM; Nilsson MA
    J Urol; 1995 Sep; 154(3):940-6. PubMed ID: 7637098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients.
    Bergsland KJ; Kinder JM; Asplin JR; Coe BJ; Coe FL
    J Urol; 2002 Jun; 167(6):2372-6. PubMed ID: 11992040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical studies of the recurrence of urolithiasis (4). Crystal formation in urine and stone recurrence].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1988 Sep; 34(9):1543-7. PubMed ID: 3213790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein calcium oxalate crystal growth inhibitor in urine.
    Worcester EM; Nakagawa Y; Coe FL
    Miner Electrolyte Metab; 1987; 13(4):267-72. PubMed ID: 3306319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of Tamm-Horsfall mucoprotein in calcium oxalate lithogenesis].
    Gambaro G; Baggio B; Favaro S; Cicerello E; Marchini F; Borsatti A
    Nephrologie; 1984; 5(4):171-2. PubMed ID: 6441892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface phase transition of hydrated calcium oxalate crystal in the presence of normal and stone-formers' urine.
    Akbarieh M; Tawashi R
    Scanning Microsc; 1990 Jun; 4(2):387-93; discussion 393-4. PubMed ID: 2402611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas.
    Laube N; Hergarten S; Hoppe B; Schmidt M; Hesse A
    J Urol; 2004 Jul; 172(1):355-9. PubMed ID: 15201810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of urine composition and calcium salt crystallization properties in standardized volume-adjusted 12-h night urine from normal subjects and calcium oxalate stone formers.
    Bek-Jensen H; Tiselius HG
    Urol Res; 1997; 25(5):365-72. PubMed ID: 9373919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and pathogenetic mechanisms in hyperuricosuric calcium oxalate renal stone disease.
    Favus MJ; Coe FL
    Scand J Urol Nephrol Suppl; 1980; 53():171-7. PubMed ID: 6937993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects.
    Robert M; Boularan AM; Delbos O; Guiter J; Descomps B
    Urol Int; 1998; 60(1):41-6. PubMed ID: 9519420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones.
    Evan AP; Coe FL; Gillen D; Lingeman JE; Bledsoe S; Worcester EM
    Anat Rec (Hoboken); 2008 Mar; 291(3):325-34. PubMed ID: 18286613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic urinary correlates of calcium oxalate dihydrate in renal stones.
    Asplin JR; Lingeman J; Kahnoski R; Mardis H; Parks JH; Coe FL
    J Urol; 1998 Mar; 159(3):664-8. PubMed ID: 9474121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute caffeine effects on urine composition and calcium kidney stone risk in calcium stone formers.
    Massey LK; Sutton RA
    J Urol; 2004 Aug; 172(2):555-8. PubMed ID: 15247728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of citrate on the different phases of calcium oxalate crystallization.
    Tiselius HG; Berg C; Fornander AM; Nilsson MA
    Scanning Microsc; 1993 Mar; 7(1):381-9; discussion 389-90. PubMed ID: 8316807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of 3' vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis.
    Mossetti G; Rendina D; Viceconti R; Manno G; Guadagno V; Strazzullo P; Nunziata V
    Nephrol Dial Transplant; 2004 Sep; 19(9):2259-65. PubMed ID: 15213319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Uronic-acid-rich protein: a new glycoprotein inhibiting the crystallization of calcium oxalate in vitro].
    Atmani F; Lacour B; Daudon M
    Nephrologie; 1996; 17(3):157-62. PubMed ID: 9064564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?
    Kavanagh JP; Laube N
    J Urol; 2006 Feb; 175(2):766-70. PubMed ID: 16407047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New pathophysiologic aspects of nephrolithiasis].
    Hess B
    Schweiz Med Wochenschr; 1989 Jul; 119(26):929-34. PubMed ID: 2678432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitaxial deposition of calcium oxalate on uric acid rich stone matrix is induced by a 29 kDa protein.
    Srinivasan S; Kalaiselvi P; Varalakshmi P
    Clin Chim Acta; 2006 Feb; 364(1-2):267-74. PubMed ID: 16139257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.